Home » Pfizer Nabs Extended Indication for Prevnar 13
Pfizer Nabs Extended Indication for Prevnar 13
Pfizer has received the greenlight from the FDA to stretch the age indication for its pneumococcal 13-valent conjugate vaccine Prevnar 13, to include adults between the ages of 18 and 49.
The vaccine — which is designed to prevent pneumonia and invasive diseases caused by streptococcus pneumoniae — is now the only pneumococcal vaccine approved for patients aged 6 weeks and over, according to the company.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May